We recently published a list of Top 20 Falling Stocks with Unusual Volume. In this article, we are going to take a look at ...

Pharmaceutical company Novo Nordisk will expand its production site in Montes Claros, Brazil, creating 600 jobs.

Novo Nordisk , the producer of Ozempic, Wegovy and other medications, will invest 6.4 billion reais ($1.09 billion) in Brazil ...

The Montes Claros site in Brazil is just one of many that Novo Nordisk has poured billions of dollars into as part of efforts to scale manufacturing capabilities. There was also the $16.5bn ...

Novo Nordisk has invested 6.4bn Brazilian reais ($1.09bn) to expand its facility in Brazil as the company ramps up efforts to increase production of its flagship glucagon-like peptide 1 receptor ...

Novo Nordisk is set to benefit from a $150B market by 2030, with strong earnings potential and a favorable 14x forward P/E.

Ironically, Ozempic and Wegovy, as with many of Novo Nordisk’s other products ... to invest billions to expand its production site in Brazil, and it recently saw some management changes.

While much of the recent GLP-1 saga has been written in the U.S., Novo Nordisk continues to expand its semaglutide empire across the globe and make inroads into large markets like Brazil.

Novo Nordisk invests $1.05B in Brazil factory to boost GLP-1 drug production, including Wegovy and Ozempic, creating 600 jobs by 2028 in Montes Claros.